| Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2745 | 2018 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1618 | 2020 |
| NTRK fusion-positive cancers and TRK inhibitor therapy E Cocco, M Scaltriti, A Drilon Nature reviews Clinical oncology 15 (12), 731-747, 2018 | 1362 | 2018 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1212 | 2019 |
| Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ... The Lancet Oncology 21 (4), 531-540, 2020 | 926 | 2020 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 840 | 2017 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 786 | 2020 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 759 | 2018 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 733 | 2020 |
| Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping PK Paik, A Drilon, PD Fan, H Yu, N Rekhtman, MS Ginsberg, L Borsu, ... Cancer discovery 5 (8), 842-849, 2015 | 638 | 2015 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 636 | 2017 |
| Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas A Drilon, L Wang, A Hasanovic, Y Suehara, D Lipson, P Stephens, J Ross, ... Cancer discovery 3 (6), 630-635, 2013 | 571 | 2013 |
| Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... JAMA oncology 5 (10), 1411-1420, 2019 | 553 | 2019 |
| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532-2537, 2018 | 515 | 2018 |
| NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ... Modern Pathology 33 (1), 38-46, 2020 | 506 | 2020 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 470 | 2020 |
| Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions JF Hechtman, R Benayed, DM Hyman, A Drilon, A Zehir, D Frosina, ... The American journal of surgical pathology 41 (11), 1547-1551, 2017 | 447 | 2017 |
| Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ... The Lancet Oncology 17 (12), 1653-1660, 2016 | 445 | 2016 |
| Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations A Drilon, SHI Ou, BC Cho, DW Kim, J Lee, JJ Lin, VW Zhu, MJ Ahn, ... Cancer discovery 8 (10), 1227-1236, 2018 | 439 | 2018 |
| Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ... Clinical Cancer Research 22 (14), 3618-3629, 2016 | 439 | 2016 |
